Literature DB >> 31680191

The role of acetylation sites in the regulation of p53 activity.

Yun Wang1, Yaqi Chen2, Qiang Chen3, Xiuyuan Zhang2, Hongye Wang2, Zhonghua Wang4, Jian Wang5, Chunyan Tian6.   

Abstract

As a "genomic guardian", p53 mainly functions as a transcription factor that regulates downstream targets responsible for cell fate control, and the activity of p53 is tightly regulated by a complex network that include an abundance of post-translational modifications. Notably, acetylation of p53 at many positions has been demonstrated to play a major role in accurate p53 regulation and cell fate determination. However, no evidence has been provided to compare the effect of acetylation at different sites on p53 regulation. Here, we constructed six acetylation-defective p53 mutants that lysine was substituted by arginine at residues 120, 164, 305, 320, 370/372/373 or 381/382/386, respectively, and determined their effects on p53 activity systematically. Our results showed that all six mutants exhibited diminished transactivation ability and selective regulation of target genes expression through distinct mechanisms. Specifically, lysine 370/372/373 and 381/382/386 mutations decreased p53 stability, and lysine 305 mutation reduced p53 phosphorylation level at serine 15, while lysine 120 and 164 mutations decreased p53 acetylation level at lysine 382. Collectively, these data indicate that acetylation of p53 at different sites has diverse regulatory effects on p53 transcriptional activity through different mechanisms.

Entities:  

Keywords:  Acetylation; Acetylation-defective mutant; Post-translational modifications; Regulation; p53

Mesh:

Substances:

Year:  2019        PMID: 31680191     DOI: 10.1007/s11033-019-05141-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  8 in total

1.  Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.

Authors:  Eswar Shankar; Mitali Pandey; Shiv Verma; Ata Abbas; Mario Candamo; Rajnee Kanwal; Sanjeev Shukla; Gregory T MacLennan; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2020-05-11       Impact factor: 4.784

Review 2.  The Pathophysiological Role of CoA.

Authors:  Aleksandra Czumaj; Sylwia Szrok-Jurga; Areta Hebanowska; Jacek Turyn; Julian Swierczynski; Tomasz Sledzinski; Ewa Stelmanska
Journal:  Int J Mol Sci       Date:  2020-11-28       Impact factor: 5.923

3.  Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice via p53/PPARα signaling.

Authors:  Yin Cai; Hao Liu; Erfei Song; Lin Wang; Jindong Xu; Yi He; Dengwen Zhang; Liyan Zhang; Kenneth King-Yip Cheng; Leigang Jin; Min Wu; Shiming Liu; Dake Qi; Liangqing Zhang; Gary D Lopaschuk; Sheng Wang; Aimin Xu; Zhengyuan Xia
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

4.  Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1.

Authors:  Xiahui Li; Shujing Li; Bowen Li; Yanan Li; Sattout Aman; Kangkai Xia; Yuxi Yang; Bashir Ahmad; Huijian Wu
Journal:  NPJ Precis Oncol       Date:  2021-03-19

5.  ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation.

Authors:  Xiuyuan Zhang; Qijian Zheng; Xiuying Yue; Zhanna Yuan; Jiming Ling; Yanzhi Yuan; Yanying Liang; Aihua Sun; Yuchen Liu; Hui Li; Kaikun Xu; Fuchu He; Jian Wang; Jin Wu; Chunling Zhao; Chunyan Tian
Journal:  J Exp Clin Cancer Res       Date:  2022-02-28

Review 6.  Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53.

Authors:  Mayra A Marques; Guilherme C de Andrade; Jerson L Silva; Guilherme A P de Oliveira
Journal:  Front Mol Biosci       Date:  2022-08-25

Review 7.  Regulating tumor suppressor genes: post-translational modifications.

Authors:  Ling Chen; Shuang Liu; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-06-10

Review 8.  p53 signaling in cancer progression and therapy.

Authors:  Hany E Marei; Asmaa Althani; Nahla Afifi; Anwarul Hasan; Thomas Caceci; Giacomo Pozzoli; Andrea Morrione; Antonio Giordano; Carlo Cenciarelli
Journal:  Cancer Cell Int       Date:  2021-12-24       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.